3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
2
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Breast
1
Conditions
Lung Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Uterine Cervical Neoplasms
1
Small Cell Lung Carcinoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
NSCLC
1
Mesothelioma
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Small Cell
1
Breast Neoplasms
1
Interventions
pembrolizumab
30
Carboplatin
13
Trastuzumab
8
Paclitaxel
7
Nivolumab
7
Cisplatin
6
Ipilimumab
5
Cetuximab
5
Bevacizumab
5
Taxes
4
Pemetrexed
4
Specimen Handling
3
Irinotecan
3
Docetaxel
3
Cyclophosphamide
3
Biopsy
3
tisotumab vedotin
2
temsirolimus
2
spartalizumab
2
sargramostim
2
pertuzumab
2
lenvatinib
2
fludarabine
2
epacadostat
2
enzalutamide
2
aldesleukin
2
X-Rays
2
Ritonavir
2
Psychiatric Rehabilitation
2
Oxaliplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
Diphenhydramine
×
Thoracic
×
Clear all
NCT04237090
2020-10-12
PREMED-F1
Ciusss de L'Est de l'Île de Montréal
Phase 3
Completed
27 enrolled